A Google search on “diet and eczema” may be more misleading than helpful, warns pediatric dermatologist Sandipan Dhar.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

Outcomes were evaluated among children born between April 1980 and June 2019 by using data from 12 observational birth ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced new data from its preclinical study of ZL-1503, the Company’s ...

Ivarmacitinib, also known as oral SHR0302, is not yet approved by the FDA, with trials currently exploring its utility in ...

The Canine Atopic Dermatitis Treatment Market size is expected to experience a considerable valuation bump, from USD 1,182.60 million in 2024 to USD 1,620.50 million in 2034. The updated report points ...

Arcutis Biotherapeutics has enrolled the first child in an open-label Phase II trial of Zoryve (roflumilast) for atopic ...

EMA’s veterinary medicinal products committee recommends marketing authorization to Elanco’s Zenrelia to treat atopic dermatitis in dogs: Greenfield, Indiana Monday, June 16, ...

Phase 2 study to evaluate investigational, once-daily ZORYVE .05% in infants as young as 3 months to less than 2 years with atopic dermatitisAtopic dermatitis impacts 9.6 million children in the ...

Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

Ilunocitinib tablets are currently available in Brazil, Canada and Japan, in addition to the US. Elanco noted that, once the ...